These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26726023)

  • 21. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
    Acharya SK; Bhatia V; Sreenivas V; Khanal S; Panda SK
    Gastroenterology; 2009 Jun; 136(7):2159-68. PubMed ID: 19505424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
    Chen MF; Li RC; Chen CH; Gao XC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
    Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
    Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
    Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
    Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letter: Hyperammonemia and hepatic encephalopathy in the dog.
    Gutnick MJ
    J Am Vet Med Assoc; 1976 Jan; 168(1):3-4. PubMed ID: 1245442
    [No Abstract]   [Full Text] [Related]  

  • 26. [In liver cirrhosis, not every "ammonia lowering drug" improves neuropsychiatric deficit].
    MMW Fortschr Med; 2001 Mar; 143(9):58. PubMed ID: 11288540
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
    Kircheis G; Wettstein M; Dahl Sv; Häussinger D
    Metab Brain Dis; 2002 Dec; 17(4):453-62. PubMed ID: 12602521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic encephalopathy in dogs and cats.
    Lidbury JA; Cook AK; Steiner JM
    J Vet Emerg Crit Care (San Antonio); 2016 Jul; 26(4):471-87. PubMed ID: 27060899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
    Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
    Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
    Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
    Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF; McPhail MJW
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperammonemia and hepatic encephalopathy in the dog.
    Strombeck KR; Weiser MG; Kaneko JJ
    J Am Vet Med Assoc; 1975 Jun; 166(11):1105-8. PubMed ID: 1173366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
    Ndraha S; Hasan I; Simadibrata M
    Acta Med Indones; 2011 Jan; 43(1):18-22. PubMed ID: 21339541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hyperammonemia in liver failure.
    Jover-Cobos M; Khetan V; Jalan R
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):105-10. PubMed ID: 24281376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Options in the treatment of hepatic encephalopathy].
    Petersen KU
    Med Monatsschr Pharm; 2015 May; 38(5):160-4. PubMed ID: 26364405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
    Sidhu SS; Sharma BC; Goyal O; Kishore H; Kaur N
    Hepatology; 2018 Feb; 67(2):700-710. PubMed ID: 28749571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute hyperammonemia after L-asparaginase administration in a dog.
    Lyles SE; Kow K; Milner RJ; Buckley GJ; Bandt C; Baxter KJ
    J Vet Emerg Crit Care (San Antonio); 2011 Dec; 21(6):673-8. PubMed ID: 22316261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED.
    Montes-Cortés DH; Novelo-Del Valle JL; Olivares-Corichi IM; Rosas-Barrientos JV; Jara LJ; Cruz-Domínguez MP
    Am J Emerg Med; 2018 Sep; 36(9):1570-1576. PubMed ID: 29352675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful management of clinical signs associated with hepatic encephalopathy with manual therapeutic plasma exchange in a dog.
    Culler CA; Reinhardt A; Vigani A
    J Vet Emerg Crit Care (San Antonio); 2020 May; 30(3):312-317. PubMed ID: 32077185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
    Butterworth RF
    Can J Gastroenterol Hepatol; 2019; 2019():8182195. PubMed ID: 31183339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.